Colonial River Wealth Management LLC Sells 1,345 Shares of Merck & Co., Inc. (NYSE:MRK)

Colonial River Wealth Management LLC lowered its position in shares of Merck & Co., Inc. (NYSE:MRKFree Report) by 12.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 9,800 shares of the company’s stock after selling 1,345 shares during the period. Colonial River Wealth Management LLC’s holdings in Merck & Co., Inc. were worth $1,068,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Ruedi Wealth Management Inc. lifted its holdings in Merck & Co., Inc. by 180.2% during the 3rd quarter. Ruedi Wealth Management Inc. now owns 311 shares of the company’s stock worth $32,000 after buying an additional 200 shares during the period. AlphaMark Advisors LLC acquired a new position in Merck & Co., Inc. during the 4th quarter worth about $34,000. Valued Wealth Advisors LLC acquired a new position in Merck & Co., Inc. during the 4th quarter worth about $42,000. TFO Wealth Partners LLC lifted its holdings in Merck & Co., Inc. by 108.1% during the 3rd quarter. TFO Wealth Partners LLC now owns 464 shares of the company’s stock worth $48,000 after buying an additional 241 shares during the period. Finally, Ameliora Wealth Management Ltd. acquired a new position in Merck & Co., Inc. during the 3rd quarter worth about $50,000. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Price Performance

Shares of NYSE MRK opened at $130.35 on Wednesday. The stock has a fifty day simple moving average of $125.45 and a two-hundred day simple moving average of $113.20. Merck & Co., Inc. has a 1-year low of $99.14 and a 1-year high of $133.10. The firm has a market cap of $330.13 billion, a price-to-earnings ratio of 931.07, a price-to-earnings-growth ratio of 0.52 and a beta of 0.38. The company has a current ratio of 1.25, a quick ratio of 1.00 and a debt-to-equity ratio of 0.89.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last announced its quarterly earnings data on Thursday, February 1st. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.12. Merck & Co., Inc. had a return on equity of 9.33% and a net margin of 0.61%. The business had revenue of $14.63 billion during the quarter, compared to analyst estimates of $14.49 billion. During the same period in the prior year, the company earned $1.62 earnings per share. Merck & Co., Inc.’s revenue was up 5.8% compared to the same quarter last year. Analysts anticipate that Merck & Co., Inc. will post 8.59 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, April 5th. Shareholders of record on Friday, March 15th will be given a dividend of $0.77 per share. The ex-dividend date is Thursday, March 14th. This represents a $3.08 annualized dividend and a dividend yield of 2.36%. Merck & Co., Inc.’s dividend payout ratio is currently 2,200.00%.

Insiders Place Their Bets

In other Merck & Co., Inc. news, insider Joseph Romanelli sold 1,000 shares of the stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $124.89, for a total transaction of $124,890.00. Following the sale, the insider now owns 19,569 shares in the company, valued at $2,443,972.41. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Merck & Co., Inc. news, insider Joseph Romanelli sold 1,000 shares of the stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $124.89, for a total transaction of $124,890.00. Following the sale, the insider now owns 19,569 shares in the company, valued at $2,443,972.41. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Steven Mizell sold 50,694 shares of the stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $126.65, for a total value of $6,420,395.10. Following the sale, the executive vice president now owns 23,619 shares in the company, valued at approximately $2,991,346.35. The disclosure for this sale can be found here. Company insiders own 0.20% of the company’s stock.

Analysts Set New Price Targets

MRK has been the topic of a number of recent analyst reports. StockNews.com raised Merck & Co., Inc. from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 2nd. Truist Financial reaffirmed a “buy” rating and set a $142.00 price target (up from $139.00) on shares of Merck & Co., Inc. in a research note on Thursday, March 28th. TD Cowen raised Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and upped their price target for the stock from $125.00 to $135.00 in a research note on Thursday, January 4th. TheStreet lowered Merck & Co., Inc. from a “b+” rating to a “c+” rating in a report on Monday, March 4th. Finally, UBS Group boosted their price objective on Merck & Co., Inc. from $135.00 to $148.00 and gave the stock a “buy” rating in a report on Friday, February 2nd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $129.71.

Check Out Our Latest Report on Merck & Co., Inc.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Further Reading

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.